Staurosporine

Catalog No.S1421 Synonyms: CGP 41251

Staurosporine Chemical Structure

Molecular Weight(MW): 466.53

Staurosporine is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.

Size Price Stock Quantity  
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Caspase-8, 9, 3, 6, PARP, and cleaved PARP were detected in POTEG overexpressed cells and control cells with or without STS treatment.

    Mol Carcinog, 2018, 57(7):886-895. Staurosporine purchased from Selleck.

    Intracellular concentration of HSF1-phosphoserine 326, total HSF1, S6 kinase-phosphothreonine-389, total S6 kinase and β-actin, without or with heat shock in HeLa cells pretreated with mTOR inhibitors rapamycin (30 nM) and KU0063794 (2 uM) and kinase inhibitor staurosporine (100 nM) for 2 hr. Relative levels of HSF1-phosphoserine 326 in cells after the various treatments were determined by densitometric analysis of X-ray films, normalized to untreated cells (lane 1), and are indicated below the representation of the immunoblots.

    PLoS One 2012 7(6), e39679. Staurosporine purchased from Selleck.

  • J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

    J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

Purity & Quality Control

Choose Selective PKC Inhibitors

Biological Activity

Description Staurosporine is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.
Targets
PKCα [1]
(Cell-free assay)
c-Fgr [2]
(Cell-free assay)
phosphorylase kinase [2]
(Cell-free assay)
PKCη [1]
(Cell-free assay)
PKCγ [1]
(Cell-free assay)
2 nM 2 nM 3 nM 4 nM 5 nM
In vitro

Staurosporine, a microbial alkaloid, significantly inhibits protein kinase C from rat brain with IC50 of 2.7 nM. Staurosporine displays strong inhibitory effect against HeLa S3 cells with IC50 of 4 nM. [1] Staurosporine also inhibits a variety of other protein kinases, including PKA, PKG, phosphorylase kinase, S6 kinase, Myosin light chain kinase (MLCK), CAM PKII, cdc2, v-Src, Lyn, c-Fgr, and Syk with IC50 of 15 nM, 18 nM, 3 nM, 5 nM, 21 nM, 20 nM, 9 nM, 6 nM, 20 nM, 2 nM, and 16 nM, respectively. [2] Staurosporine (1 μM) induces >90% apoptosis in PC12 cells. Consistently, Staurosporine treatment induces a rapid and prolonged elevation of intracellular free calcium levels [Ca2+]i, accumulation of mitochondrial reactive oxygen species (ROS), and subsequent mitochondrial dysfunction. [3] The apoptosis of MCF7 cells induced by Staurosporine can be enhanced by the expression of functional caspase-3 via caspase-8 activation and Bid cleavage. [4] Staurosporine treatment at 1 μM only partially inhibits IL-3-stimulated Bcl2 phosphorylation but completely blocks PKC-mediated Bcl2 phosphorylation. [5] Staurosporine induces apoptosis of human foreskin fibroblasts AG-1518, depending on the lysosomal cathepsins D mediated cytochrome c release and caspase activation. [6] In addition to activating the classical mitochondrial apoptosis pathway, Staurosporine triggers a novel intrinsic apoptosis pathway, relying on the activation of caspase-9 in the absence of Apaf-1. [7]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human HeLa cells MU\DfZRwfG:6aXRCpIF{e2G7 MUe0PEBp NYjUb|V{S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWOYTDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVRmNTB4IN88UU4> MVyyNVM5QDF7MR?=
human colon cancer cell line (LoVo cells) NH;pWlNRem:uaX\ldoF1cW:wIHHzd4F6 M2XOZWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iY3;sc44h[2GwY3XyJINmdGxibHnu[UApVG:YbzDj[YxteylidYPpcochVVSWIHHzd4F6NCCLQ{WwQVAvODBzIN88UU4> M4L4Z|EyPTlzNUC1
human LoVo cells NV\lelJuWHKxbHnm[ZJifGmxbjDhd5NigQ>? MWG0PEB1dyB5MjDo MmrBRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCOb2\vJINmdGy|IHHmeIVzKDR6IITvJFczKGi{czDifUBOXFRiYYPzZZk> M1LrUlIzOTh{OUK5
P19 cells NIn5ZY5HfW6ldHnvckBie3OjeR?= NX35ToFHUW6qaXLpeIlwdiCxZjDQcIF1\WyndD3k[ZJqfmWmIHfyc5d1cCCoYXP0c5IhemWlZYD0c5IhcW5iUEG5JINmdGy|LDDJR|UxRTBwMECyJO69VS5? NH7aeJgyPTd5MUSxPS=>
human BJ cells NUHUZXl6S3m2b4TvfIlkyqCjc4PhfS=> NYLheo9CPzJiaB?= MY\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDCTkBk\WyuczDh[pRmeiB5MjDodpMh[nliQ3HsZ4VqdiCDTTDhd5NigSxiSVO1NF0xNjByMjFOwG0v MWiyNlkzOTB6MR?=
human HT-29 cells MXjGeY5kfGmxbjDhd5NigQ>? Mn22NkBp MX\F[oZm[3Rib36gcYl1d2Oqb37kdolidCCvZX3idoFv\SCyb4TlcpRq[WxiaX6gbJVu[W5iSGStNlkh[2WubIOgZYZ1\XJiMjDodpMhfXOrbnegTmMuOSC|dHHpcolv\yCkeTDmcJVwemW|Y3XuZ4Uh[XO|YYm= MW[yNVQzQDN5NR?=
human A549 cells NGLqXnBEgXSxdH;4bYPDqGG|c3H5 MlnBO|IhcA>? MYXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDzeYxnd3Kqb3ThcYlv\SCEIH3leIhw\A>? MUOxPFQ5PDd5NR?=
human HT-29 cells M3;WcmZ2dmO2aX;uJIF{e2G7 M1;EcmlvcGmkaYTpc44hd2ZibXn0c4Npd26mcnnhcEBu\W2kcnHu[UBxd3SnboTpZYwhcW5iaIXtZY4hUFRvMkmgZ4VtdHNidYPpcochUkNzIHT5[UB{fGGrbnnu[{BjgSCobIXvdoV{[2WwY3WgdIxifGVicnXh[IVzKGG|c3H5MEBKSzVyPUKuOUBvVQ>? NH;vUW0zOTVzM{K5Ny=>
human HT-29 cells NUnTfWs1TnWwY4Tpc44h[XO|YYm= NI\IOFkzKGh? Mo[5TY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCKVD2yPUBk\WyuczDhd5Nme3OnZDDy[YR2[3Srb36gc4YhdWm2b3Poc45lemmjbDDt[Y1jemGwZTDwc5RmdnSrYXygZYZ1\XJiMjDodpMh[nlidYPpcochUkNzIIP0ZYlvcW6pIHL5JIZtfW:{ZYPj[Y5k\SClZXzsMYJie2WmIHHzd4F6NCCHQ{WwQVIvPiCwTT6= NWTIRoZGOjF7N{OxNFE>
Sf9 cells M1vueWZ2dmO2aX;uJIF{e2G7 M2Hse2lvcGmkaYTpc44hd2ZiaIXtZY4hW3mtIHX4dJJme3OnZDDpckBU\jliY3XscJMtKEmFNUC9N{BvVS5? NXn5S4h3OTh6MkO3PFQ>
human HUVEC MYDQdo9tcW[ncnH0bY9vKGG|c3H5 NY\ucmNFPDhidH:gO|IhcA>? M{HzS2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSGXWSWMh[W[2ZYKgOFghfG9iN{KgbJJ{KGK7IF3UWEBie3OjeR?= MlrBNlIyQDJ7Mkm=
P19 cells M{PIU2Z2dmO2aX;uJIF{e2G7 NF\hXHFKdmirYnn0bY9vKG:oIGDyc5RmcW5iS3nuZZNmKEFiaX6gVFE6KGOnbHzzMEBKSzVyPUSgcm0v M4X6Z|E2PzdzNEG5
Sf9 cells M1nWeWZ2dmO2aX;uJIF{e2G7 NV3MO3lvUW6qaXLpeIlwdiCxZjDoeY1idiCIeX6g[ZhxemW|c3XkJIlvKFOoOTDj[YxteyCjZoTldkAyKG2rbjDifUBGVEmVQTDpckBxemW|ZX7j[UBw\iBzIIXtc4wwVCCDVGC= M1jWe|E4OzF3OEWz
Sf21 cells MoCwSpVv[3Srb36gZZN{[Xl? MWDJcohq[mm2aX;uJI9nKEqDS{Og[ZhxemW|c3XkJIlvKFOoMkGgZ4VtdHNuIFnDOVA:PiCwTT6= MXuxO|A5QDB3OR?=
human colon carcinoma cell line HCT116 M4q5O2Z2dmO2aX;uJIF{e2G7 NV\rcVlCS2:wY3XueJJifGmxbjDy[ZF2cXKnZDDmc5Ih\3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4h[2:ub36gZ4Fz[2mwb33hJINmdGxibHnu[UBJS1RzMU[sJGlEPTB;NjDuUU4> NIe5foQyPTV|N{O0OS=>
human ST486 cells Mn;QVJJwdGmoZYLheIlwdiCjc4PhfS=> NH7p[Zg1QCC2bzC3NkBp MoTZRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCVVES4OkBk\WyuczDh[pRmeiB2ODD0c{A4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVchdk1w NEfFVGczOjF6MkmyPS=>
human MDA-MB-231 cells MkfDR5l1d3SxeHnjxsBie3OjeR?= NH;Odow4OiCq NGLYV4NEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDzeYxnd3Kqb3ThcYlv\SCEIH3leIhw\CxiR1m1NF04NjFibl2u NGTme3MyQDR6NEe3OS=>
P19 cells NVjhdJIyTnWwY4Tpc44h[XO|YYm= NWnmd|RPUW6qaXLpeIlwdiCxZjDDfYNtcW5vZHXw[Y5l\W62IHvpcoF{\SBzIHnuJHAyQSClZXzsd{whUUN3ME24JI5ONg>? NXrGZnFOOTV5N{G0NVk>
human DLD1 cells MWTQdo9tcW[ncnH0bY9vKGG|c3H5 M4DFbFQ5NTd{IHi= Ml;XRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCGTFSxJINmdGy|IHHmeIVzKDR6IITvJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9PUBvVS5? MVWyNlE5Ojl{OR?=
insect cells MXvGeY5kfGmxbjDhd5NigQ>? NVnsc3B3UW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDQbY0yKGW6cILld5Nm\CCrbjDpcpNm[3RiY3XscJMh[nliSGTSSkwhUUN3ME2xNEBvVS5? NUXDTVU3OTlzN{mwO|Y>
V79 MZ cells NUf3PY1{TnWwY4Tpc44h[XO|YYm= Mm\BTY5pcWKrdHnvckBw\iCqdX3hckBidGSxc4Tldo9v\SC|eX70bIF{\SCneIDy[ZN{\WRiaX6gWlc6KE2cIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yh[Wymb4P0[ZJwdmVic4nueIhme2m|LDDJR|UxRTFzIH7NMi=> NIjVcWEzPDR{MkWxPS=>
P19 cells MVXGeY5kfGmxbjDhd5NigQ>? M1ThbGlvcGmkaYTpc44hd2ZiVnHzZ5Vt[XJiZX7kc5Rp\WyrYXyg[5Jwf3SqIH\hZ5RweiC{ZXPldJRweiCrbjDQNVkh[2WubIOsJGlEPTB;MUSgcm0v M4PYXlE2PzdzNEG5
Sf9 cells MoXkSpVv[3Srb36gZZN{[Xl? M{\udFIxKG2rboO= MVXJcohq[mm2aX;uJI9nKGi3bXHuJGZ6diCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJIFnfGW{IEKwJI1qdnNiYomgSWxKW0FiaX6gdJJme2WwY3Wgc4YhOSC3bX;sM2whSVSSLDDJR|UxRTF3IH7NMi=> NWL2[XZtOTd|MUW4OVM>
human PBMC NVTOeYs1TnWwY4Tpc44h[XO|YYm= MlfyNlQhcA>? MlGwV5VxeHKnc4Ppc44hd2ZiSVyyJJBzd2S3Y4Tpc44hcW5iaIXtZY4hWEKPQzDh[pRmeiB{NDDodpMh[nliRVzJV2EtKEmFNUC9NVYhdk1w NYPEZoh5OTh3OEWwOFY>
human A549 cells MX\DfZRwfG:6aXRCpIF{e2G7 MnfXOFghcA>? MXjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmgMEBKSzVyPUKwJI5ONg>? MlH1NlU5OjV7M{S=
human CEM cells Mn;VR5l1d3SxeHnjxsBie3OjeR?= MVG3NkBp NGTMbXBEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBETU1iY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGNidGOnaX6gRW0h[XO|YYmsJGlEPTB;MkOgcm0v NYTkXHlMOjJ7MkGwPFE>
human HeLa cells NHLU[XBEgXSxdH;4bYPDqGG|c3H5 MXy0PEBp MXzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MkWgcm0v MUGyOVgzPTl|NB?=
human PC3 cells M2PWTWN6fG:2b4jpZ:Kh[XO|YYm= M{\XblQ5KGh? Mon0R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVGM{KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmgMEBKSzVyPUOxJI5ONg>? NEe3bIUzPTh{NUmzOC=>
human SF268 cells NVf1PHpyS3m2b4TvfIlkyqCjc4PhfS=> M3SwT|Q5KGh? NUOwSJhWS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0Z{NkigZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NF01PCCwTT6= MVWyNVUyOzJ7NB?=
human MCF7 cells NYK2dWtsS3m2b4TvfIlkyqCjc4PhfS=> M1nQNFQ5KGh? MlHrR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUWwJI5ONg>? MYOyNVM5QDF7MR?=
HEK293 cells MUDDfZRwfG:6aXRCpIF{e2G7 MX[3NkBp NHzIfZREgXSxdH;4bYNqfHliYXfhbY5{fCCKRVuyPVMh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSnclfsc{Bie3OjeTygTWM2OD13NjDuUU4> MYqyOFc3OzJ4Mh?=
HUE cells NWi2VWJWTnWwY4Tpc44h[XO|YYm= NXXifpQ2QTBibXnudy=> M4fHcWlvcGmkaYTpc44hd2ZiVlXHSnIzKGmwIFjVSUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIG\FS2YucW6mdXPl[EBifXSxcHjvd5Bpd3K7bHH0bY9vKHS{ZXH0[YQh\m:{IEmwJI1qdnNiYnXmc5JmKF[HR1[gZ4hidGynbnflJIJ6KEWOSWPBMEBKSzVyPUewJI5ONg>? MYiyNFE4ODF4Mx?=
human A431 cells MofZR5l1d3SxeHnjxsBie3OjeR?= MmHsNlQhKGh? MWTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOFMyKGOnbHzzJIFnfGW{IEK0JIhzeyC3c3nu[{BCdm6neHnuJHZmTkmWQz;wdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pIHL5JG1VXCCjc4PhfUwhUUN3ME23NEBvVS5? NHrwU5kzOjV2MUC1NS=>
human Jurkat cells MUPQdo9tcW[ncnH0bY9vKGG|c3H5 MlXYRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDKRWs{KGW6cILld5NqdmdiSVyyMZN1cW23bHH0[YQhcHWvYX6gTpVzc2G2IHPlcIx{NCCLQ{WwQVcyKG6PLh?= M1jueFE6PDJ5MkCz
HEK293 cells NFLLRWRHfW6ldHnvckBie3OjeR?= MnjDTY5pcWKrdHnvckBw\iCLTD24JJJmdGWjc3WgZpkhUEWNMkmzJINmdGy|IHX4dJJme3OrbnegVGtENWKndHGyMEBKSzVyPUe3JI5ONg>? MlS3NVU4PzF2MUm=
human KE-97 cells NHjtZ2NEgXSxdH;4bYPDqGG|c3H5 NV\pbIVpPzJiaB?= M1nZXGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtGNTl5IHPlcIx{KGGodHXyJFczKGi{czDifUBE\WyuVHn0doUuT2yxIHz1cYlv\XOlZX70JINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTNizszNMi=> MUeyOFMzQDJ6Mx?=
human CHOK1 cells MmTSR5l1d3SxeHnjxsBie3OjeR?= NWDFZlVJPDhiaB?= NYjreo8{S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS0iRS{GgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5Nige,:jDDJR|UxRTBwMUOg{txONg>? NXz0RlA3OjF3MUOyPVQ>
mouse NIH/3T3 cells NVHGTFMxS3m2b4TvfIlkyqCjc4PhfS=> MmTRPVYhcA>? NWm4Zll3S3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhVkmKL{PUN{Bk\WyuczDh[pRmeiB7NjDodpMh[nliU2LCJIF{e2G7LDDJR|UxRTBwMjFOwG0v NYnQUmlbOjR|NkG1NlE>
human A2780 cells MUjDfZRwfG:6aXRCpIF{e2G7 M{PLR|k3KGh? MojHR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVI4QDBiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME2wMlIh|ryPLh?= NHLkTm8zPDN4MUWyNS=>
human 8505C cells MXvDfZRwfG:6aXRCpIF{e2G7 M2nFN|k3KGh? NGn4cnREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckA5PTB3QzDj[YxteyCjZoTldkA6PiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvOiEQvF2u MU[yOFM3OTV{MR?=
human 518A2 cells MmTUR5l1d3SxeHnjxsBie3OjeR?= MmHLPVYhcA>? MkHlR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gOVE5STJiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JHNTSiCjc4Phfg+9lCCLQ{WwQVAvOiEQvF2u NGXyN|YzPDN4MUWyNS=>
human HuH7 cells NHTpNnREgXSxdH;4bYPDqGG|c3H5 NG[zWFU4OiCq MVLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIeWg4KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2cnWtS4xwKGy3bXnu[ZNk\W62IHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlMh|ryPLh?= MkDsNlQ{Ojh{OEO=
FL5.12-Akt1 cells M{\1e3Bzd2yrZnXyZZRqd25iYYPzZZk> MXPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IF\MOU4yOi2Da4SxJINmdGy|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlI6KM7:TT6= M4XkdFE3PDB|NkK2
human MiaPaCa-2 cells NHT4XGhRem:uaX\ldoF1cW:wIHHzd4F6 NVfFPFh1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNbYFR[UOjLUKgZ4VtdHNuIFnDOVA:OC5|NzFOwG0v M3\hPFE3PDF|N{iw
human BGC823 cells NFexbJVEgXSxdH;4bYPDqGG|c3H5 M3;t[|czKGh? NXr1fnlkS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSkeFOEKzJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1emVvR3zvJIx2dWmwZYPj[Y51KGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwM{ig{txONg>? NXLJPJRkOjR|MkiyPFM>
human MCF7 cells MWHDfZRwfG:6aXRCpIF{e2G7 MUW5OkBp MVHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDTVmIh[XO|YYmsJGlEPTB;MD60JO69VS5? MXWyOFM3OTV{MR?=
human A549 cells NYnoVHF{S3m2b4TvfIlkyqCjc4PhfS=> MVO5OkBp NVSxNnVVS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA6PiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvPiEQvF2u NUW5PFA4OjR|NkG1NlE>
HEK293 cells MV3DfZRwfG:6aXRCpIF{e2G7 M3zzcWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEiHS{K5N{Bk\WyuczygSWM2OD1{IN88UU4> NYnFVYpROjV|MU[zNVc>
human Raji cells  M{C3PWN6fG:2b4jpZ:Kh[XO|YYm= MWXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDSZYpqKGOnbHzzMEBGSzVyPUKg{txONg>? MVOyOVMyPjNzNx?=
human HepG2 cells NED2WXFEgXSxdH;4bYPDqGG|c3H5 MWLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{whTUN3ME2yJO69VS5? NGW1NVgzPTNzNkOxOy=>
human BJ cells MWLDfZRwfG:6aXRCpIF{e2G7 MmHCR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRmoh[2WubIOsJGVEPTB;MjFOwG0v NW\hT41oOjV|MU[zNVc>
human U937 cells NGPRRlFEgXSxdH;4bYPDqGG|c3H5 MXzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDVPVM4KGOnbHzzMEBKSzVyPUKg{txONg>? Ml\UNVcxQDhyNke=

... Click to View More Cell Line Experimental Data

In vivo In the gerbil and rat ischemia models, Staurosporine pretreatment (0.1-10 ng) before ischemia prevents neuronal damage in a dose-dependent manner, suggesting the involvement of PKC in CAl pyramidal cell death after ischemia. [8]

Protocol

Kinase Assay:

[1]

+ Expand

Enzyme assay and binding assay:

Protein kinase C is assayed in a reaction mixture (0.25 mL) containing 5 μmol of Tris/HCl, pH 7.5, 2.5 μmol of magnesium acetate, 50 μg of histone II S, 20 μg of phosphatidylserine, 0.88 μg of diolein, 125 nmol of CaCl2, 1.25 nmol of [γ-32]ATP (5-10 × 104 cpm/nmol) and 5 μg of partially purified enzyme. The binding of [3H]PDBu to protein kinase C is determined: Reaction mixture (200 μL contained 4 μmo1 of Tris/malate, pH 6.8, 20 μmol of KCl, 30 nmol of CaC12, 20 μg of phosphatidylserine, 5 μg of partially purified protein kinase C, 0.5% (final concentration) of DMSO,10 pmol of [3H]PDBu (l-3 × 104 cpm/pmol) and 10 μL of various amounts of Staurosporine.
Cell Research:

[3]

+ Expand
  • Cell lines: PC12
  • Concentrations: Dissolved in DMSO, final concentration 1 μM
  • Incubation Time: ~32 hours
  • Method:

    Cells are exposed to Staurosporine for ~32 hours. Cells are fixed in 4% paraformaldehyde and stained with the DNA-binding dye Hoechst 33342. Cells are visualized under epifluorescence illumination, and the percentage of apoptotic cells (cells with condensed and fragmented DNA) is determined.


    (Only for Reference)
Animal Research:

[8]

+ Expand
  • Animal Models: Male Mongolian gerbils or male Wistar rats subjected to transient ischemia
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~10 ng
  • Administration: Stereotaxically administered into the bilateral CAl subfield of the hippocampus
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 4 mg/mL (8.57 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 466.53
Formula

C28H26N4O3

CAS No. 62996-74-1
Storage powder
in solvent
Synonyms CGP 41251

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00301938 Completed Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Acute Promyelocytic Leukemia (M3)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Myelodysplastic/Myeloproliferative Neoplasms|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) December 2005 Phase 1
NCT00098956 Completed Extensive Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer National Cancer Institute (NCI) January 2005 Phase 2
NCT00082017 Terminated Lymphoma Large-Cell Ki-1|Lymphoma T-Cell National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 5 2004 Phase 2
NCT00072267 Completed Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer University Health Network Toronto|National Cancer Institute (NCI) January 2004 Phase 2
NCT00072189 Terminated Recurrent Melanoma|Stage IV Melanoma National Cancer Institute (NCI) November 2003 Phase 2
NCT00030888 Unknown status Kidney Cancer University of California San Francisco|National Cancer Institute (NCI) December 2002 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PKC Signaling Pathway Map

Related PKC Products0

Tags: buy Staurosporine | Staurosporine supplier | purchase Staurosporine | Staurosporine cost | Staurosporine manufacturer | order Staurosporine | Staurosporine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID